ReCode Therapeutics’ Post

Your website is more important than you think 💡 Stopwatch Creative work rebranding Mahajan Therapeutics, later led to an acquisition by BayMark Health Services! Learn more on stopwatchcreative.com

“Drug development is an inherently risky business, so it is important that every partnership is built on a foundation of mutual trust and confidence.”  Well said, Madee Gooriah PharmD, MS.  I came across this Ipsen blog and thought I’d share as it sums up the importance of effective collaboration in achieving the best patient outcomes.  https://rebrand.ly/dejjbas #Ipsen #Medidata #LifeSciences

Get an inside look at how Prime Therapeutics is reshaping the PBM landscape!

Despite ambitious goals, Pear Therapeutics faced go-to-market challenges and revenue difficulties. Now, nearly one year following Pear’s bankruptcy, the company’s assets have been acquired by four prominent players in the industry. What does this mean for DTx? Let's discuss! Join the waitlist for an insightful discussion on: 🔍 Broader implications for the digital health industry. 🚀 Confidence in digital therapeutics technology and future market shaping. 💡 Revenue generation strategies with innovative product lines. Meeting Full. JOIN THE WAITLIST NOW ➡️ https://lnkd.in/g-ujacYw #digitalhealth #digitaltherapeutics #healthtech

🚀𝐀𝐜𝐜𝐞𝐥𝐞𝐫𝐚𝐭𝐢𝐧𝐠 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: 𝐊𝐲𝐯𝐞𝐫𝐧𝐚 𝐒𝐞𝐜𝐮𝐫𝐞𝐬 𝐀𝐝𝐝𝐢𝐭𝐢𝐨𝐧𝐚𝐥 𝐅𝐃𝐀 𝐅𝐚𝐬𝐭 𝐓𝐫𝐚𝐜𝐤, 𝐈𝐏𝐎 𝐨𝐧 𝐭𝐡𝐞 𝐇𝐨𝐫𝐢𝐳𝐨𝐧 🌐 𝗜𝗻 𝗝𝗮𝗻𝘂𝗮𝗿𝘆 𝟮𝟬𝟮𝟰, Kyverna Therapeutics accelerates into another FDA fast track following IPO plans. As KYV-101 moves through the clinical trial stage, Kyverna will have more regular and convenient communication with U.S. regulators thanks to the fast track tag—this time for refractory progressive multiple sclerosis. Additionally, if and when Kyverna files a new #drug application, it allows the #business to request for priority review, which shortens the FDA approval review period to six months. Recently, Kyverna was able to obtain a fast-track tag for myasthenia gravis and approve the entry of its autologous CD19-targeting cell treatment into a phase 2 open-label trial for #patients suffering from #multiplesclerosis. 𝑳𝒐𝒐𝒌 𝒂𝒕 𝒐𝒖𝒓 𝑪𝒐𝒓𝒓𝒆𝒍𝒂𝒕𝒆𝒅 𝑹𝒆𝒑𝒐𝒓𝒕👉:https://bit.ly/3RPw6Qb #FDAFastTrack #IPOJourney #BiotechAdvancement #healthcareinnovation #acceleratingsuccess #biopharma #prophecymarketinsights

In this K-Cast episode, Diana Brixner, discusses the level of clinical evidence payers should expect and require from non-prescription digital health tools compared to FDA-approved digital therapeutics! Brixner offers insight as to where the biggest gaps in evidence generation for digital therapeutics come from. Watch here: https://bit.ly/4drOvLE #ManagedCare #DigitalHealth

Recruiting patients for clinical trials has historically been a delayed and drawn-out process - but it doesn’t have to be.    With an accelerated support effort, patient recruitment targets for clinical trials can be met three months before the scheduled delivery rate, as this graph shows.   We discuss further here: https://lnkd.in/gC6w7iYX #clinicaltrials #pharma #patients

Did you know that DTx has positive benefits for patient outcomes and engagement? Check the latest report below.

#DYK about 16 million Americans experience gastroparesis symptoms, and the majority go untreated as there is no chronic treatment option?     CinDome Pharma is enrolling the #envision3d clinical trial to investigate deudomperidone (CIN-102) as a potential, chronic therapy for gastroparesis and fill this unmet medical need. Learn more about our work at: cindome.com and www.gastroparesistrial.com #GastroparesisAwarenessMonth #GastroparesisAwareness #LivingWithGP